Unveiling the role of tyrosine kinases in doxorubicin-induced cardiotoxicity and beyond

Edoardo Lazzarini^{1

2

3}, Claudia Altomare^{1

2

3}, Lucio Barile^{1

2

3}

Affiliations

¹ Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Ente Ospedaliero Cantonale, Via Chiesa 5, Bellinzona 6500, Switzerland.
² Laboratories for Translational Research, Ente Ospedaliero Cantonale, Via Chiesa 5, Bellinzona 6500, Switzerland.
³ Euler Institute, Faculty of Biomedical Sciences, Università della Svizzera italiana (USI), Via la Santa 1, Lugano 6962, Switzerland.

Editorial

Edoardo Lazzarini et al. Cardiovasc Res. 2025.

. 2025 May 6;121(4):530-531.

doi: 10.1093/cvr/cvaf035.

Edoardo Lazzarini^{1

2

3}, Claudia Altomare^{1

2

3}, Lucio Barile^{1

2

3}

¹ Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Ente Ospedaliero Cantonale, Via Chiesa 5, Bellinzona 6500, Switzerland.
² Laboratories for Translational Research, Ente Ospedaliero Cantonale, Via Chiesa 5, Bellinzona 6500, Switzerland.
³ Euler Institute, Faculty of Biomedical Sciences, Università della Svizzera italiana (USI), Via la Santa 1, Lugano 6962, Switzerland.

No abstract available

Conflict of interest statement

Conflict of interest: none declared.

Thousand and one amino acid protein kinase 1 suppression improves doxorubicin-induced cardiomyopathy by preventing cardiomyocyte death and dysfunction.
Suga T, Kitani T, Kogure M, Oishi M, Ito F, Hoshino A, Ogata T, Ikeda K, Matoba S. Suga T, et al. Cardiovasc Res. 2025 May 6;121(4):601-613. doi: 10.1093/cvr/cvaf022. Cardiovasc Res. 2025. PMID: 39964965